AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceNamed GroupsHealth Care
Transplantation, HomologousGraft vs Host DiseaseHematopoietic Stem Cell TransplantationBone Marrow TransplantationGraft SurvivalKidney TransplantationGraft RejectionTransplantation ConditioningLiver TransplantationTransplantation, AutologousImmunosuppressive AgentsTransplantation ChimeraStem Cell TransplantationCyclosporineTissue DonorsHematologic NeoplasmsTransplantation, IsogeneicGraft vs Tumor EffectChronic DiseaseTreatment OutcomeTransplantation ImmunologyHeart TransplantationRats, Inbred LewPeripheral Blood Stem Cell TransplantationTime FactorsRecurrenceLung TransplantationHistocompatibility TestingMyeloablative AgonistsHistocompatibilityHematopoietic Stem Cell MobilizationGraft vs Leukemia EffectVidarabineRemission InductionRetrospective StudiesBlood Component RemovalBusulfanMultiple MyelomaWhole-Body IrradiationSurvival AnalysisCord Blood Stem Cell TransplantationLeukemiaOrgan TransplantationIslets of Langerhans TransplantationKidney DiseasesImmunosuppressionLymphocyte DepletionAcute DiseaseSurvival RateGranulocyte Colony-Stimulating FactorLeukemia, Myeloid, AcuteAllograftsPrecursor Cell Lymphoblastic Leukemia-LymphomaAntigens, CD34T-LymphocytesTransplantationHematopoietic Stem CellsGraft Occlusion, VascularCell TransplantationPancreas TransplantationKidneyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNuclear FamilyLymphocyte TransfusionMelphalanSalvage TherapyDisease-Free SurvivalMyelodysplastic SyndromesHLA AntigensLeukapheresisFollow-Up StudiesTransplantation, HeterotopicLife TablesLiving DonorsSiblingsCombined Modality TherapyLeukemia, MyeloidTransplantation ToleranceNeoplasm, ResidualSkin TransplantationHepatic Veno-Occlusive DiseaseBlood CellsMice, Inbred C57BLAntibodies, NeoplasmUnrelated DonorsCytomegalovirus InfectionsImmunomagnetic SeparationAntineoplastic Combined Chemotherapy ProtocolsBlood DonorsMice, Inbred BALB CCyclophosphamideBone Marrow CellsPostoperative ComplicationsLymphoma, Non-HodgkinIsoantigensFetal Tissue TransplantationFetal BloodLymphomaTissue and Organ ProcurementHeart-Lung Transplantation
GVHDDiseaseBlood and Marrow TransplantationHaematopoietic Cell TransplantationCGvHDHSCTCell TransplantationHematopoietic Stem CellTransplantsMortalitySevere aplastic anemiaCurativeLymphocyticStem CellPatientsUmbilicalSurvivalAplasticComplicationsChemotherapyAGVHDPatient's own cellsHostBone marrowClinicalOncologyHematologyMyeloid leukemiaDonor-recipientTreatment
GVHD50
  • Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. (medscimonit.com)
  • Twenty-three patients experienced acute GVHD and 17 developed chronic GVHD. (medscimonit.com)
  • Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs. (wikipedia.org)
  • GvHD can also occur after a blood transfusion, known as Transfusion-associated graft-versus-host disease or TA-GvHD if the blood products used have not been gamma irradiated or treated with an approved leukocyte reduction system. (wikipedia.org)
  • Mucosal damage to the vagina can result in severe pain and scarring, and appears in both acute and chronic GvHD. (wikipedia.org)
  • About one-third to one-half of allogeneic transplant recipients will develop acute GvHD. (wikipedia.org)
  • Graft versus host disease (GVHD) is an immune-mediated condition resulting from a complex interaction between donor and recipient adaptive immunity. (medscape.com)
  • [ 1 ] Acute GVHD describes a distinctive syndrome of dermatitis (see the image below), hepatitis, and enteritis developing within 100 days after allogeneic hematopoietic cell transplantation (HCT). (medscape.com)
  • Chronic GVHD describes a more diverse syndrome developing after day 100. (medscape.com)
  • In addition to allogeneic HCT, procedures associated with high risk of GVHD include transplantation of solid organs containing lymphoid tissue and transfusion of unirradiated blood products. (medscape.com)
  • Autologous graft versus host disease (GVHD) involving the skin of a patient's arm appeared shortly after signs of engraftment appeared. (medscape.com)
  • Chronic GVHD may be an extension of acute GVHD, may occur de novo in patients who never have clinical evidence of acute GVHD, or may emerge after a quiescent interval after acute GVHD resolves. (medscape.com)
  • Vascular injury has been seen in patients with acute graft versus host disease (GVHD) in the skin. (nih.gov)
  • We aimed to see whether vascular injury mediated by cytotoxic T lymphocytes and microvessel loss arises in patients with chronic GVHD. (nih.gov)
  • We investigated eight patients with acute GVHD and ten with chronic GVHD for signs of endothelial injury and microvessel loss by measurement of von Willebrand factor (vWF) in plasma and blood vessel density in biopsy samples taken from lesional skin. (nih.gov)
  • Substantial blood vessel loss may lead to impaired blood perfusion and tissue fibrosis, the hallmark lesion of chronic GVHD. (nih.gov)
  • Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). (hindawi.com)
  • Graft versus host disease (GVHD) represents the most frequent cause of TRM. (hindawi.com)
  • Shortly before graft infusion, GVHD prophylaxis (immunosuppression) is started. (hindawi.com)
  • Eight patients from the first NGFR-HSV-TK-studies developed acute ( n = 6) or chronic GvHD ( n = 2), which resolved after treatment with GCV alone in seven of eight patients. (frontiersin.org)
  • Understand the pathophysiology of graft-versus-host disease (GvHD). (ebmt.org)
  • Diagnose and stage acute and chronic GvHD. (ebmt.org)
  • Identify different treatment strategies for acute and chronic GvHD, including pharmacological and non-pharmacological approaches. (ebmt.org)
  • The inclusion of ATG resulted in a significantly lower rate of chronic GVHD after allogeneic transplantation than the rate without ATG. (bmj.com)
  • The survival rate was similar in the two groups, but the rate of a composite end point of chronic GVHD-free survival and relapse-free survival was higher with ATG. (bmj.com)
  • The plain English version would read: "In this two year, open-label trial, our company's antihuman T-lymphocyte immune globulin (ATG) halved the rate of chronic graft-versus-host disease (GVHD) in people who had previously undergone allogeneic haematopoietic stem-cell transplantation, but made no difference to mortality. (bmj.com)
  • The day-100 cumulative incidence of grade III-IV, but not grade II-IV acute graft versus host disease (GVHD) was higher in African Americans compared to Caucasians (29% vs. 13%, p=0.006). (aamds.org)
  • Though the 5-year cumulative incidence of chronic GVHD was not significantly different between the racial groups, African Americans were more likely to have extensive chronic GVHD compared to Caucasians (72% vs. 49%, p=0.06). (aamds.org)
  • Our data suggest some of the observed survival differences between Caucasians and African Americans may be explained by higher rates of acute GVHD and severity of chronic GVHD. (aamds.org)
  • Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. (stembook.org)
  • Acute and chronic graft-versus-host disease (GVHD) are significant threats to QOL. (usf.edu)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
  • Graft-versus-host disease (GVHD) is a life-threatening complication that can occur after certain stem cell or bone marrow transplants . (medlineplus.gov)
  • There are two types of GVHD: acute and chronic. (medlineplus.gov)
  • Symptoms in both acute and chronic GVHD range from mild to severe. (medlineplus.gov)
  • Chronic GVHD usually starts more than 3 months after a transplant, and can last a lifetime. (medlineplus.gov)
  • Many cases of acute or chronic GVHD can be treated successfully. (medlineplus.gov)
  • The incidence of grade II-IV acute and chronic graft versus host disease (GvHD) was 23.6% and 12.9% respectively. (nih.gov)
  • Oral manifestations are diagnosed in approximately 80% of patients with chronic GVHD. (bvsalud.org)
  • Clinical manifestations of chronic GVHD are similar to autoimmune collagen vascular disease and the two main types of cutaneous chronic GVHD are lichenoid and sclerodermatous. (bvsalud.org)
  • Chronic or late GVHD may appear months after transplantation and remain present for years [1, 5]. (bvsalud.org)
  • Oral manifestations, commonly expressed by atrophy, erythema, and lichnoides lesions on buccal and labial mucosa, have been diagnosed in approximately 80% of patients with chronic GVHD [1, 11]. (bvsalud.org)
  • Lichenoid and sclerodermatous are the two main types of cutaneous chronic GVHD [14]. (bvsalud.org)
  • Herein, we present one case of chronic GVHD with scleroderma-like lesions in skin and oral cavity with patient complaint of normal oral function loss. (bvsalud.org)
  • Patient underwent allogeneic BTM and two days later developed acute GVHD on intestine. (bvsalud.org)
  • GVHD disease is the most common consequence of allogeneic BMT and the skin is the most commonly affected organ [5, 13]. (bvsalud.org)
  • Graft-versus-host disease (GVHD) is a complication that occurs following allo-HSCT and is a major driver of posttransplant morbidity and mortality [ 2 ]. (biomedcentral.com)
  • In transplants for leukemia in CR1 and CP1, preparative regimen and immunoprophylaxis posttransplant were not associated significantly with the probability of acute GVHD greater than or equal to grade 2, extensive chronic GVHD, relapse, survival, or LFS. (ashpublications.org)
  • In bone marrow transplantation for leukemia, counterflow centrifugation is a useful technique for the prevention of GVHD. (ashpublications.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
Disease60
  • In the clinical setting, graft-versus-host disease is divided into acute and chronic forms, and scored or graded on the basis of the tissue affected and the severity of the reaction. (wikipedia.org)
  • In the classical sense, acute graft-versus-host disease is characterized by selective damage to the liver, skin (rash), mucosa, and the gastrointestinal tract. (wikipedia.org)
  • Newer research indicates that other graft-versus-host disease target organs include the immune system (the hematopoietic system, e.g., the bone marrow and the thymus) itself, and the lungs in the form of immune-mediated pneumonitis. (wikipedia.org)
  • Chronic graft-versus-host disease also attacks the above organs, but over its long-term course can also cause damage to the connective tissue and exocrine glands. (wikipedia.org)
  • The chronic form of graft-versus-host disease (cGvHD) normally begins 90 to 600 days post-transplant. (wikipedia.org)
  • Not to be confused with Host-versus-graft disease . (wikipedia.org)
  • Mouse colon impacted by acute graft-versus-host disease. (wikipedia.org)
  • Micrographs of grades of skin graft-versus-host disease: Ranging from grade I GvHR (with minimal vacuolization in the epidermis) to grade II GvHR (with vacuolization and dyskeratotic bodies) to grade III GvHR (with sub epidermal cleft formation) and finally to grade IV GvHR (with separation of the dermis from the epidermis). (wikipedia.org)
  • Four patients developed acute, grade 2 to 3, graft- versus -host disease and four patients developed extensive chronic graft- versus -host disease. (aacrjournals.org)
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is applied successfully to the treatment of many hematopoietic malignancies, but remains limited by severe acute graft-versus-host-disease (aGvHD). (frontiersin.org)
  • Study end points were the probabilities of overall survival, leukemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM) and chronic graft- versus -host disease. (haematologica.org)
  • Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. (stembook.org)
  • Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. (stembook.org)
  • In the evolving landscape of graft-versus-host disease management, staying abreast of current and projected epidemiological trends is vital. (researchandmarkets.com)
  • Developed for decision-makers, this Graft vs. Host Disease - Epidemiology Forecast - 2032 report provides a detailed panorama on the incidence and prevalence of this severe complication of allogeneic stem cell transplantation in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. (researchandmarkets.com)
  • Armed with historical and forecasted data, the report elucidates the severity and organ-specific grading of graft-versus-host disease cases. (researchandmarkets.com)
  • This comprehensive knowledge is paramount for informed decision-making and strategic planning in the quest to tackle graft-versus-host disease. (researchandmarkets.com)
  • Graft-versus-host disease is a potentially serious complication of allogeneic stem cell transplantation. (researchandmarkets.com)
  • Total allogenic transplant cases of graft-versus-host disease in the 7MM range from ~24,440 in 2022 to ~29,600 in 2032. (researchandmarkets.com)
  • Graft-versus-host disease is categorized into two types: acute and chronic graft-versus-host disease. (researchandmarkets.com)
  • In the 7MM, the acute graft-versus-host disease incident cases were ~10,340 in 2022, which are likely to increase to ~12,360 by 2032. (researchandmarkets.com)
  • Furthermore, in the 7MM, the 5-year prevalence of chronic graft-versus-host disease was ~23,080 in 2022, which is likely to increase to ~26,300 cases by 2032. (researchandmarkets.com)
  • An assessment of the degree of involvement of these organs determines the severity of acute graft-versus-host disease. (researchandmarkets.com)
  • The overall severity of chronic graft-versus-host disease is classified as mild, moderate, or severe based on organ-specific grading (number of organs and severity). (researchandmarkets.com)
  • Approximately ~45% of 5-year prevalent cases of chronic graft-versus-host disease belong to the moderate category. (researchandmarkets.com)
  • Skin (~59%), oral mucosa (~53%), eyes (~53%), lungs (~43%), liver (~29%), joints and fascia (~28%), and gastrointestinal (~23%) are the most often affected organs by chronic graft-versus-host disease. (researchandmarkets.com)
  • In 2022, the 7MM mortality-adjusted treated acute graft-versus-host disease patients were ~9,830 in first-line, and these cases are expected to increase to ~11,740 cases by 2032. (researchandmarkets.com)
  • This "Graft vs. Host Disease - Epidemiology Forecast - 2032" report delivers an in-depth understanding of Graft vs. Host Disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. (researchandmarkets.com)
  • the disease is a side effect that is common after an allogeneic bone marrow transplant. (researchandmarkets.com)
  • The two main types of Graft vs. Host Disease are acute Graft vs. Host Disease and Chronic Graft vs. Host Disease. (researchandmarkets.com)
  • As an allogeneic transplant recipient, the patient might experience either form of Graft vs. Host Disease, either form, or neither. (researchandmarkets.com)
  • Graft-versus-host disease is a potentially serious complication in a recipient of an allograft (usually a haematopoietic stem cell transplant) that arises from the attack of recipient tissues (such as the skin, liver or gut) by donor-derived T cells. (nature.com)
  • establish a convolutional neural network-based model to predict acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation. (nature.com)
  • Chronic graft- versus -host disease (cGvHD) is a major cause of morbidity after hematopoietic stem cell transplantation (HSCT). (haematologica.org)
  • As a result, HSCT is often attributed to an increased risk of health complications, the most severe being chronic graft- versus -host disease (cGvHD). (haematologica.org)
  • Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. (harvard.edu)
  • This includes bone and cartilage repair, cell types into which MSCs readily differentiate, and immune conditions such as graft versus host disease and autoimmune conditions that utilize the MSC's immune suppressive properties. (biomedcentral.com)
  • The transplantation of stem cells from a healthy donor (allogeneic) offers the chance of cure for patients with an aggressive form of chronic lymphocytic leukemia (CLL), irrespective of genetic prognostic factors and the prior course of the disease. (disabled-world.com)
  • Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X Trial. (disabled-world.com)
  • Graft-versus-host disease and graft-versus-leukemia responses. (medlineplus.gov)
  • Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. (soulsource.com)
  • Chronic graft versus host disease (cGVHD) is the most common consequence of allogeneic bone marrow transplantation, and it is associated with morbidity and mortality. (bvsalud.org)
  • Chronic graft-vs-host disease (cGVHD) is the most common complication following allogeneic BMT [10]. (bvsalud.org)
  • Many other clinical conditions present substantial skin fibrosis and may be potentially confused with Scleroderma, sometimes leading to a wrong diagnosis (eosinophilic fasciitis, systemic amyloidosis, scleromyxedema, graft-versus-host disease, progeroid disorders, stiff skin syndrome). (bvsalud.org)
  • Kynurenine Pathway Activation and Deviation to Anthranilic and Kynurenic Acid in Fibrosing Chronic Graft-Versus-Host Disease, Orsatti et al. (mendeley.com)
  • 7 In the recently completed LenaRIC study patients undergoing allo-SCT with reduced-intensity conditioning received lenalidomide for 12 months from day 35 post-transplantation, with DLI for mixed chimerism or persistent disease. (medicalupdateonline.com)
  • It may be associated with chronic H pylori infection, gluten-sensitive enteropathy, and Menetrier disease. (medscape.com)
  • Chronic graft-versus-host disease (cGVHD) is a long-term complication of allogeneic hematopoietic stem cell transplantation. (elsevierpure.com)
  • Approximately 30-70% of patients who have undergone allogeneic (allo) hematopoietic stem cell transplantation (HSCT) eventually experience chronic graft-versus-host disease (cGVHD). (biomedcentral.com)
  • OBJECTIVES: - To investigate efficacy of topical clobetasol 0.05% oral rinse for oral chronic graft versus-host disease (cGVHD) ELIGIBILITY: - Patients age 12-99 years with clinically significant oral cGVHD. (getwellsoon.ai)
  • High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype. (cdc.gov)
  • Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. (cdc.gov)
  • Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. (cdc.gov)
  • Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. (cdc.gov)
  • Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. (cdc.gov)
  • We use three different medical environments to analyze the mechanisms behind these conditions: systemic sclerosis, pregnancy-related pathologies, and chronic graft versus host disease (cGVHD). (cnrs.fr)
  • Transplantation-related issues such as graft versus host disease, graft failure, chronic immunosuppressive therapy, and transplantation-related mortality should be carefully considered prior to proceeding with this approach. (medscape.com)
  • Covariance pattern models were used to determine predictors of regret over time, including baseline characteristics and post-alloHCT outcomes (acute or chronic graft-versus-host-disease, disease recurrence). (cdc.gov)
  • The risk of regretting transplantation was 17.5 percentage points (95% confidence interval, 5.5-29.7 percentage points) greater in patients who developed disease recurrence after HCT compared with patients who did not. (cdc.gov)
Blood and Marrow Transplantation7
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 26 (10). (duke.edu)
  • Dr. Kurtzberg is an internationally renowned expert in pediatric hematology/oncology, pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation, and novel applications of cord blood and birthing tissues in the emerging fields of cellular therapies and regenerative medicine. (duke.edu)
  • 10 Data from the European Society for Blood and Marrow Transplantation (EBMT) megafile database indicates that the graft-versus-tumour effect achieved with allo-SCT is weaker and PFS rates lower in MM than in other types of haematological cancers. (medicalupdateonline.com)
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018 8 25 (1): 100-106. (cdc.gov)
  • 69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (cdc.gov)
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 6 25 (10): 1975-1983. (cdc.gov)
  • Biology of Blood and Marrow Transplantation. (umn.edu)
Haematopoietic Cell Transplantation1
CGvHD5
  • 3 cGvHD has been estimated to develop in 25% of pediatric and 60% of adult HSCT survivors, may cause chronic and often irreversible organ damage, and has a 10-25% mortality rate. (haematologica.org)
  • Over past four months after allogeneic BTM she developed cGVHD in eyes, mouth, liver, lungs and skin. (bvsalud.org)
  • The 5-year overall survival and cGVHD recurrence-free survival rates were significantly higher in EW-cGVHD than Dp-cGVHD (96% vs. 68%, p = 0.017 and 84% vs. 41%, p = 0.002, respectively). (elsevierpure.com)
  • An estimated 30-70% of allo-HSCT recipients, who survive more than 100 days after transplantation, develop cGVHD. (biomedcentral.com)
  • They occur on a systemic level in systemic sclerosis, they are localized in pregnancy-related diseases and they are induced by an external graft in cGVHD. (cnrs.fr)
HSCT12
  • The potential role of elastin in patients with myeloid leukemia treated with hematopoietic stem cell transplantation (HSCT) has not been investigated so far. (medscimonit.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only curative modality for many hematological disorders. (hindawi.com)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • Recently, we and others have shown that allogeneic hematopoietic stem cell transplantation (allo-HSCT) may represent a valid treatment option in leukemic myeloid sarcoma. (haematologica.org)
  • Hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for patients with non-malignant diseases as well as high-risk and refractory hematopoietic malignancies. (haematologica.org)
  • 1 HSCT may be followed by chronic inflammation due to tissue self-antigen mismatches among the transplant donor and recipient. (haematologica.org)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) in thalassemia remains a challenge. (nih.gov)
  • Hematopoietic stem cell transplantation (HSCT) remains an important therapy for long term remission of many malignant and nonmalignant hematological disorders [ 1 , 2 ]. (biomedcentral.com)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
Cell Transplantation57
Hematopoietic Stem Cell1
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
Transplants7
  • The US Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for reducing infections and hastening neutrophil recovery for blood cancer patients aged 12 years and older who are undergoing allogeneic umbilical cord blood stem cell transplants. (medscape.com)
  • The FDA approval was based on phase 3 testing that pitted the use of omidubicel in 62 patients against standard unmanipulated cord blood transplants in 63 patients following myeloablative conditioning. (medscape.com)
  • Overall, 87% of patients who received omidubicel achieved neutrophil recovery, vs 83% of patients with standard transplants. (medscape.com)
  • The incidence of grade 2/3 bacterial or grade 3 fungal infections 100 days following transplant was 39% with omidubicel, vs 60% with standard transplants. (medscape.com)
  • Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study. (stembook.org)
  • The projected 3-year probability of relapse was 30% (95% confidence interval [CI], range 8% to 53%) in transplants for AML in first complete remission (CR1), 35% (95% CI, 1% to 69%) after transplantation for ALL in CR1, and 38% (95% CI, 2% to 74%) after transplantation for CML in first chronic phase (CP1). (ashpublications.org)
  • Probabilities of relapse, survival, and LFS in AML-CR1 and ALL-CR1 transplants were comparable with those reported in recipients of untreated grafts. (ashpublications.org)
Mortality1
  • The only factor associated with higher non-relapse mortality was patient gender (male: 27±6% vs . female: 10±5%, P =0.04). (haematologica.org)
Severe aplastic anemia1
Curative1
Lymphocytic2
  • Chronic lymphocytic leukemia ( CLL ) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell ). (wikipedia.org)
  • In an analysis from the phase III ECOG/ACRIN E1912 trial in chronic lymphocytic leukemia (CLL) published in the Journal of Clinical Oncology, O'Connell et al found that grade 1 and 2 adverse events were significant contributors to patient-reported side-effects bother, with grade 2 events being. (ascopost.com)
Stem Cell6
  • A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. (stembook.org)
  • Before undergoing an allogeneic stem cell transplant, the patient will receive high doses of chemotherapy or radiation to destroy the diseased cells and prepare the body for the donor cells. (researchandmarkets.com)
  • What's the difference between allogeneic and autologous stem cell transplantations? (clevelandclinic.org)
  • While both treatments help your bone marrow to develop new blood cells, studies show allogeneic stem cell transplantations work by causing the donor cells to attack unhealthy cells. (clevelandclinic.org)
  • Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. (cdc.gov)
  • [ 14 ] The first successful allogeneic stem cell transplant from an HLA-identical sibling donor was reported in 1982. (medscape.com)
Patients12
  • All patients achieved initial mixed hematopoietic chimerism with two patients rejecting their graft and recovering host hematopoiesis. (aacrjournals.org)
  • The primary purpose of this study is to estimate and compare overall survival between the two arms: patients who are Very Likely to find a Matched Unrelated Donor (MUD) versus those who are Very Unlikely to find a MUD. (mayo.edu)
  • Method: observational, analytical study, carried out with 35 patients in a reference hospital for transplantation in Latin America. (bvsalud.org)
  • For conditioning for transplantation, patients were given a reduced dosage of chemotherapy so that the acute tolerance of the transplantation was very good. (disabled-world.com)
  • For a large percentage of patients, highly sensitive tests were conducted regularly to detect any remaining leukemia cells after the transplantation. (disabled-world.com)
  • PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced results for the co-primary endpoint for CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo for patients who have had a complete surgical removal of stage IIIb/c/d or stage IV melanoma. (bms.com)
  • Traditional preventive measures for nosocomial pneumonia include decreasing aspiration by the patient, preventing cross-contamination or colonization via hands of personnel, appropriate disinfection or sterilization of respiratory-therapy devices, use of available vaccines to protect against particular infections, and education of hospital staff and patients. (cdc.gov)
  • Eighty consecutive patients were transplanted with human leukocyte antigen (HLA)-identical sibling marrow for acute myelogenous leukemia (AML, N = 29), acute lymphoid leukemia (ALL, N = 23), or chronic myelogenous leukemia (CML, N = 28). (ashpublications.org)
  • The projected 3-year probability of leukemia-free survival (LFS) was 56% (95% CI, 35% to 77%) after transplantation for AML-CR1, 42% (95% CI, 16% to 69%) in patients transplanted for ALL-CR1, and 49% (95% CI, 18% to 80%) after transplantation for CML-CP1. (ashpublications.org)
  • In patients transplanted for CML-CP1, probability of relapse was higher and probability of LFS was lower than in recipients of untreated grafts. (ashpublications.org)
  • In their study of 116 patients (51 males and 65 females) with thalassemia major, males were receiving more units of RBCs per transfusion and had a higher annual transfusion volume, but with correction for weight, females were receiving a higher transfused volume per kg: 225 versus 202 mL/kg in males ( P =0.028). (medscape.com)
  • Conclusions: Among patients who underwent alloHCT and lived to 100 days, the majority did not report regretting their transplantation. (cdc.gov)
Umbilical1
  • Engraftment failure and delays, likely due to diminished cord blood unit (CBU) potency, remain major barriers to the overall success of unrelated umbilical cord blood transplantation (UCBT). (duke.edu)
Survival1
  • The 5-year probabilities of overall survival adjusted for interval from diagnosis to transplantation, and performance score was 58% for African Americans and 73% for Caucasians. (aamds.org)
Aplastic1
Complications1
  • Symptoms may occur with the development of complications of chronic H pylori gastritis, which include peptic ulcers, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma. (medscape.com)
Chemotherapy1
  • Comparisons of allogeneic HCT with autologous HCT and standard-dose chemotherapy suggest impairments in QOL and a different trajectory of recovery in allogeneic HCT, but these conclusions are limited by confounding variables. (usf.edu)
AGVHD1
  • The purpose of this study is to compare the effectiveness and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids. (mayo.edu)
Patient's own cells1
  • The main risk still remains the "graft-versus-host reaction", in which donor cells attack the patient's own cells, which are foreign to them. (disabled-world.com)
Host2
  • White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self). (wikipedia.org)
  • The efficacy of allo-SCT in MM relies on the transplanted immune system having an anti-tumour effect on the host bone marrow, the so-called graft-versus-myeloma (GvM) effect. (medicalupdateonline.com)
Bone marrow5
  • The purpose of this study is to evaluate the effects that psychological and health behavior factors have on quality of life, level if sickness, and death after blood and bone marrow transplantation. (mayo.edu)
  • Para la recolección de datos, se utilizaron los cuestionarios Functional Assessment Cancer Therapy Bone Marrow Transplantation y el COmprehensive Score for financial Toxicity. (bvsalud.org)
  • For data collection, the Functional Assessment Cancer Therapy Bone Marrow Transplantation and COmprehensive Score for Financial Toxicity questionnaires were used. (bvsalud.org)
  • Para coleta de dados, utilizaram-se os questionários Functional Assessment Cancer Therapy Bone Marrow Transplantation e COmprehensive Score for financial Toxicity. (bvsalud.org)
  • eg, bone, bone marrow, and skin grafts) Genetically identical (syngeneic [between monozygotic twins]) donor tissue (isografts) Genetically. (msdmanuals.com)
Clinical1
  • Oral lichen planus (OLP) is a chronic mucocutaneous disorder that presents in a wide range of clinical forms, such as unilateral or bilateral white striations, papules, or plaques on the buccal mucosa, labial mucosa, tongue, and gingiva. (medscape.com)
Oncology1
  • Randomization was stratified by tumor histology (squamous cell carcinoma vs. adenocarcinoma), geographic region (Asia vs. ex-Asia), and Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0 vs. 1). (merck.com)
Hematology1
  • A 27-year-old female was admitted, in a Hematology Center, in 1997, with previous diagnosis of chronic myeloid leukemia since 1994. (bvsalud.org)
Myeloid leukemia1
Donor-recipient1
  • African Americans and Caucasians were matched for age, donor-recipient HLA match, graft type and transplantation year. (aamds.org)
Treatment2
  • The means of the allogeneic group were lower than those of the autologous group in all domains, showing a significant difference in relation to additional concerns (p=0.01) and in the treatment evaluation index (p=0.04). (bvsalud.org)
  • Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. (who.int)